4.15 USD
+0.18 (+4.53%)
4.18 USD
+0.03 (+0.72%)
Taking everything into account, CTMX scores 5 out of 10 in our fundamental rating. CTMX was compared to 533 industry peers in the Biotechnology industry. CTMX has an excellent financial health rating, but there are some minor concerns on its profitability. CTMX does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year CTMX was profitable.
In the past year CTMX has reported a negative cash flow from operations.
In the past 5 years CTMX reported 4 times negative net income.
CTMX had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
CTMX has a Return On Assets of 17.70%. This is amongst the best in the industry. CTMX outperforms 96.06% of its industry peers.
CTMX's Return On Equity of 26.09% is amongst the best of the industry. CTMX outperforms 97.19% of its industry peers.
The Return On Invested Capital of CTMX (15.67%) is better than 96.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.7% | ||
| ROE | 26.09% | ||
| ROIC | 15.67% |
ROA(3y)-3.97%
ROA(5y)-11.04%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 24.66%, CTMX belongs to the top of the industry, outperforming 94.93% of the companies in the same industry.
CTMX has a better Operating Margin (20.46%) than 94.75% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.46% | ||
| PM (TTM) | 24.66% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), CTMX is creating value.
CTMX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CTMX has more shares outstanding
There is no outstanding debt for CTMX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
CTMX has an Altman-Z score of 3.92. This indicates that CTMX is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of CTMX (3.92) is better than 72.98% of its industry peers.
There is no outstanding debt for CTMX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.92 |
ROIC/WACC1.8
WACC8.68%
2.3 Liquidity
CTMX has a Current Ratio of 3.64. This indicates that CTMX is financially healthy and has no problem in meeting its short term obligations.
CTMX has a Current ratio (3.64) which is comparable to the rest of the industry.
A Quick Ratio of 3.64 indicates that CTMX has no problem at all paying its short term obligations.
With a Quick ratio value of 3.64, CTMX perfoms like the industry average, outperforming 46.72% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.64 | ||
| Quick Ratio | 3.64 |
3. Growth
3.1 Past
CTMX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 140.59%, which is quite impressive.
CTMX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -10.26%.
The Revenue has been growing by 19.15% on average over the past years. This is quite good.
EPS 1Y (TTM)140.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-228.57%
Revenue 1Y (TTM)-10.26%
Revenue growth 3Y54.7%
Revenue growth 5Y19.15%
Sales Q2Q%-82.16%
3.2 Future
CTMX is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -22.96% yearly.
CTMX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 0.34% yearly.
EPS Next Y-92.3%
EPS Next 2Y-64.72%
EPS Next 3Y-41.82%
EPS Next 5Y-22.96%
Revenue Next Year-23.36%
Revenue Next 2Y-36.94%
Revenue Next 3Y-30.4%
Revenue Next 5Y0.34%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
CTMX is valuated reasonably with a Price/Earnings ratio of 10.12.
Based on the Price/Earnings ratio, CTMX is valued cheaply inside the industry as 97.56% of the companies are valued more expensively.
CTMX is valuated cheaply when we compare the Price/Earnings ratio to 25.98, which is the current average of the S&P500 Index.
CTMX is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.12 | ||
| Fwd PE | N/A |
4.2 Price Multiples
CTMX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. CTMX is cheaper than 94.18% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 17.11 |
4.3 Compensation for Growth
A cheap valuation may be justified as CTMX's earnings are expected to decrease with -41.82% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-64.72%
EPS Next 3Y-41.82%
5. Dividend
5.1 Amount
CTMX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
4.15
+0.18 (+4.53%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners78.75%
Inst Owner Change3.03%
Ins Owners0.6%
Ins Owner Change1.18%
Market Cap703.18M
Revenue(TTM)113.63M
Net Income(TTM)28.02M
Analysts84.29
Price Target7.21 (73.73%)
Short Float %19.77%
Short Ratio7.22
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)12.22%
Min EPS beat(2)-74.27%
Max EPS beat(2)98.72%
EPS beat(4)3
Avg EPS beat(4)88.28%
Min EPS beat(4)-74.27%
Max EPS beat(4)215.22%
EPS beat(8)7
Avg EPS beat(8)121.73%
EPS beat(12)10
Avg EPS beat(12)96.64%
EPS beat(16)11
Avg EPS beat(16)69.24%
Revenue beat(2)1
Avg Revenue beat(2)-12.98%
Min Revenue beat(2)-49.71%
Max Revenue beat(2)23.76%
Revenue beat(4)3
Avg Revenue beat(4)32.06%
Min Revenue beat(4)-49.71%
Max Revenue beat(4)92.34%
Revenue beat(8)7
Avg Revenue beat(8)44.02%
Revenue beat(12)10
Avg Revenue beat(12)36.04%
Revenue beat(16)10
Avg Revenue beat(16)9.74%
PT rev (1m)22.22%
PT rev (3m)22.98%
EPS NQ rev (1m)-21.64%
EPS NQ rev (3m)12.83%
EPS NY rev (1m)10.76%
EPS NY rev (3m)113.85%
Revenue NQ rev (1m)-15.44%
Revenue NQ rev (3m)-12.16%
Revenue NY rev (1m)0%
Revenue NY rev (3m)5.59%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.12 | ||
| Fwd PE | N/A | ||
| P/S | 6.19 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 6.55 | ||
| P/tB | 6.64 | ||
| EV/EBITDA | 17.11 |
EPS(TTM)0.41
EY9.88%
EPS(NY)-0.28
Fwd EYN/A
FCF(TTM)-0.43
FCFYN/A
OCF(TTM)-0.43
OCFYN/A
SpS0.67
BVpS0.63
TBVpS0.63
PEG (NY)N/A
PEG (5Y)N/A
Graham Number2.42
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.7% | ||
| ROE | 26.09% | ||
| ROCE | 19.83% | ||
| ROIC | 15.67% | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | 20.46% | ||
| PM (TTM) | 24.66% | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-3.97%
ROA(5y)-11.04%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.72
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 7.74% | ||
| Cap/Sales | 0.09% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.64 | ||
| Quick Ratio | 3.64 | ||
| Altman-Z | 3.92 |
F-Score5
WACC8.68%
ROIC/WACC1.8
Cap/Depr(3y)42.33%
Cap/Depr(5y)55.65%
Cap/Sales(3y)1.42%
Cap/Sales(5y)2.17%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)140.59%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-228.57%
EPS Next Y-92.3%
EPS Next 2Y-64.72%
EPS Next 3Y-41.82%
EPS Next 5Y-22.96%
Revenue 1Y (TTM)-10.26%
Revenue growth 3Y54.7%
Revenue growth 5Y19.15%
Sales Q2Q%-82.16%
Revenue Next Year-23.36%
Revenue Next 2Y-36.94%
Revenue Next 3Y-30.4%
Revenue Next 5Y0.34%
EBIT growth 1Y246.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year309.72%
EBIT Next 3Y-10.1%
EBIT Next 5YN/A
FCF growth 1Y-99.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-103.53%
OCF growth 3YN/A
OCF growth 5YN/A
CYTOMX THERAPEUTICS INC / CTMX FAQ
What is the fundamental rating for CTMX stock?
ChartMill assigns a fundamental rating of 5 / 10 to CTMX.
What is the valuation status of CYTOMX THERAPEUTICS INC (CTMX) stock?
ChartMill assigns a valuation rating of 3 / 10 to CYTOMX THERAPEUTICS INC (CTMX). This can be considered as Overvalued.
How profitable is CYTOMX THERAPEUTICS INC (CTMX) stock?
CYTOMX THERAPEUTICS INC (CTMX) has a profitability rating of 4 / 10.
How financially healthy is CYTOMX THERAPEUTICS INC?
The financial health rating of CYTOMX THERAPEUTICS INC (CTMX) is 8 / 10.